 REGISTER NOW!
Refer a friend
2005 Conference
2004 Conference
2003 Conference
|
Panels
Medical Devices Panel: Launching a Breakthrough Medical Device: Lessons for the Future
The medical device industry has recently witnessed the introduction of several breakthrough products that are rapidly improving treatment options for patients, including drug-coated stents for the treatment of cardiovascular disease and artificial spinal discs for the treatment of severe lower back pain. The development and introduction of new medical devices involves not just an onerous FDA approval process, but overcoming significant reimbursement hurdles and complex commercial challenges associated with training and educating physicians and patients. This panel will highlight the best practices for overcoming the major clinical, regulatory, and commercial challenges associated with developing, launching, and effectively driving sales of innovative medical device products. Specific topics to be covered include:
- What are the common pitfalls associated with launching breakthrough medical devices? How do you best overcome those challenges?
- What are the most effective ways for training physicians on the rollout of a new medical device product?
- How will the changing regulatory and pricing environment in the medical device industry to affect the launch of future medical devices?
Panelists: - Moderator: Adam Galeon, Analyst, Visium Capital Management
- Jim Cloar, Vice President, General Manager, Thoracolumbar Spine Division, Medtronic
- Michael J. Dormer, Worldwide Chairman, Medical Devices Group, Johnson & Johnson
- Paul Mraz, CEO and Chairman, Angstrom Medica
- Blair Anderson (Andy) Rieth, Jr., Director of Investor Relations, Guidant Corporation
- Christopher Simon, Director, McKinsey & Company
[ Back to top ]
Entrepreneurship Panel: Stem Cells and Regenerative Medicine: Entrepreneurial Opportunities and Challenges
Regenerative medicine has long been heralded as the new frontier of medicine. Embryonic and adult stem cells, autologous organs, and other technologies offer great promise, though scientific, business, and political challenges remain. This panel will explore some of these obstacles and discuss the role of entrepreneurs in shaping regenerative medicine into an important health care sector. The topics include:
- The importance of enabling technologies and sector infrastructure
- Alternative technologies other than embryonic stem cells
- The role of venture capital in a sector with high capital requirement and long development time
- Optimal business models
- The role of regulatory agencies and their potential impact on US company competitiveness in stem cells and regenerative medicine
Panelists: - Moderator: Robert J. Easton, Chairman and Co-Founder, Easton Associates
- Reni J. Benjamin, PhD, Senior Biotechnology Analyst, Rodman and Renshaw
- William M. Caldwell, IV, Chief Executive Officer, Advanced Cell Technology
- Martin McGlynn, President, CEO, and Director, StemCells, Inc.
- Steven Nichtberger, MD, President and CEO, Tengion, Inc
- Stephen W. Webster, President, CEO, and Director, Neuronyx
- Robert F. Willenbucher, MD, VP, Venture Leader, The Stem Cell Internal Venture, Johnson and Johnson Internal Ventures
[ Back to top ]
Finance Panel: Financing growth - from M&A to offshore investments
With healthcare's large stake in the economy and its high-growth performance over the past few years, many analysts predict ongoing deal flow in the industry. Some of the factors driving this deal activity include aging populations in the US, Asia and Europe, a weak biotech IPO market, more in-licensing and specialty pharma activity, and increased contributions from the private equity sector. However, in the future environment, healthcare sectors are not equally attractive and traditional valuation methodologies will require a new approach. This panel will explore the financial growth opportunities and challenges within the healthcare industry including:
- Has value become an issue of regulatory risk more than R&D potential? How will new regulations reducing trading blocs and encouraging riskier offshore investments (e.g., China, India, Russia) impact valuations?
- What is the significance and impact of recent healthcare M&A and is this a trend for the upcoming future?
- Will consumer-directed health plans affect M&A trends and valuations?
- How will the emergence of new global markets play a role in financing healthcare? Is international money coming to the US and is domestic money chasing international innovation?
- Are there opportunities resulting from the decentralization of national healthcare systems?
Panelists: - Moderator: Peter Baird, Principle, McKinsey & Co.
- Spencer Hoffman, Principal, Safeguard Scientifics
- David Piacquad, Vice President, Ventures and Business Development, Johnson & Johnson Development Corporation
- Steven St. Peter, MD, General Partner, MPM Capital
- Maureen Spivak, Managing Director, Health Care Group, Merrill Lynch
- Shelly L. Wall, Vice President, Morgan Stanley Venture Partners
[ Back to top ]
Lagging R&D Productivity: What Should the Pharmaceutical Industry Do To Address This Dilemma?
The Pharmaceutical industry's R&D spend continues to rise as annual approvals of new molecular entities have declined for almost a decade. Meanwhile, Big Pharma is increasingly looking outside its own discovery facilities for novel drug candidates: 20% of 2004 sales came from in-licensed drugs. This panel will examine the R&D productivity conundrum and whether the R&D function should be re-configured away from the current centralized, bench-to-bedside "blockbuster" model by considering the following questions:
- Will in-licensing become the primary method for fueling the pipeline? Is there an ideal stage for in-licensing?
- What are the outsourcing trends in research and/or development? How have these impacted internal operations and partner relationships?
- Will there be further focus on acquisitions or creating strategic alliances in biopharmaceutical development?
- Are there ways, such as pay for discovery incentives, to internally restructure research & development within Big Pharma to increase productivity?
- How will modifications to the current model affect the competitive dynamics of the industry over the next five years and beyond?
Panelists: - Moderator: Charley Beever, Vice President, Booz Allen Hamilton
- Robert Bagdorf, MD, Senior Director, Licensing & Development, Pfizer
- Roland Gerritsen van der Hoop, MD, PhD, Sr. VP of R&D and Regulatory Affairs, Endo Pharmaceuticals
- Vlad Hogenhuis, MD, Vice President, New Products, Worldwide Human Health Marketing, Merck & Co.
- Paul Spreen, Vice President and Head, Global Sales, Quintiles
- J. Anthony Ware, MD, Vice President, Lilly Research Laboratories, Global Brand Leader, Prasugrel, Eli Lilly & Co.
[ Back to top ]
Biotechnology Panel: Commercial Challenges of Bringing Personalized Medicine to the Market
Five years after the publication of the results of the Human Genome Project, personalized medicine, the use of marker-assisted diagnosis and targeted therapies derived from an individual's molecular profile, has produced only a handful of commercial successes. As the personalized medicine industry evolves, both established and new companies have learned from prior failures and are adapting their strategies to capitalize on the commercial opportunities of genomics and proteomics technology. This panel will explore the challenges of bringing personalized medicine to the market including:
- What business model is sustainable for a personalized medicine company? Must genomics and proteomics companies forward integrate into drug development?
- What are the regulatory hurdles of personalized medicine, and how can they be overcome?
- What unique reimbursement issues will these products face, and how will companies successfully address them?
- How will the marketing of personalized medicine products differ from the existing marketing strategies of pharmaceutical and biotechnology companies?
- What do the first wave of targeted therapies, such as Erbitux and Herceptin, teach us about the challenges that lie ahead?
Panelists: - Moderator: Marc Kozin, President of North American Practice, L.E.K. Consulting
- Chip Baird, Chief Financial Officer, PTC Therapeutics
- Stan Bernard, MD, MBA, Founder and President, Bernard Associates
- Steven Lo, Senior Director, Herceptin Marketing, Genentech
- Michael Samoszuk, MD, Chief Medical Officer, Roche Diagnostics Corporation
- Harry Stylli, PhD, MBA, President and Chief Executive Officer, Sequenom
[ Back to top ]
Payor/Provider Panel: Bridging the Gap: Optimizing Cost and Quality in a Consumer-Driven World
The Payor and Provider Panel will examine the many changes in healthcare provision ranging from Medicare Part D to the consolidation of insurance payors and the emergence of consumer driven health plans. Consumerism is a growing force in health care, and one manifestation of this trend is the emergence of consumer-directed health plans. According to a recent survey, 22% of the largest US employers offered consumer-driven plans in 2005, nearly double the number in 2004. This panel will explore the opportunities and challenges of these plans including:
- What are the long-term implications of consumers taking more responsibility for choices in health care?
- How are consumer-directed health plans addressing quality of care?
- How are consumers empowered to make informed choices?
- What role should employers, payors, providers, or other third parties play?
Panelists: - Moderator: Anne Wilkins, Vice President and Director, The Boston Consulting Group
- Jeffrey Levin-Scherz, MD, Chief Medical Officer, Partners Community HealthCare
- Don Liss, MD, Senior Medical Director, Mid-Atlantic Region, Aetna
- Michael Parkinson, MD, MPH, EVP and Chief Health and Medical Officer, Lumenos
- Dr. James Pope, Executive Vice President, Chief Medical Officer, American Healthways
- Karen Titlow, Chief Operating Officer, The Leapfrog Group
[ Back to top ]
|
